RxDoctor Payments Data

Deanna Edwards, MD

Internal Medicine · Omaha, NENPI 1851406912

Payments from drug & device makers

$1,861in general payments, 2019–2025

Across 112 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$484
  • Pfizer$147
  • Novartis$133
  • Boston Scientific$126
  • Boehringer Ingelheim$90
  • Lilly USA, LLC$89
  • plus $793 from 25 others

What the payments were for

  • Food & beverage$1,861100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,861 in reported general payments places this provider in the 80th percentile of 570 internal medicine providers in Nebraska.

See all internal medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$361,240
Medicare patients
1,378
Services billed
8,652

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide140$163,707
OzempicSemaglutide111$107,288
EliquisApixaban92$89,559
OtezlaApremilast12$63,222
JardianceEmpagliflozin58$51,258
XareltoRivaroxaban43$44,972
MyrbetriqMirabegron55$34,613
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$28,461
Tresiba Flextouch U-200Insulin Degludec49$25,574
Breo ElliptaFluticasone/Vilanterol43$24,677
JanuviaSitagliptin Phosphate26$23,977
FarxigaDapagliflozin Propanediol21$16,064
Emgality PenGalcanezumab-Gnlm11$15,917
VascepaIcosapent Ethyl24$14,145
GemtesaVibegron17$12,708

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$89$163,707140 claims
Novo NordiskOzempic$40$107,288111 claims
PfizerEliquis, Premarin, Paxlovid$147$97,718126 claims
AmgenOtezla$64$63,22212 claims
GSKTrelegy Ellipta, Breo Ellipta$11$53,13882 claims
Boehringer IngelheimJardiance$90$51,25858 claims
Johnson & JohnsonXarelto$37$44,97243 claims
Astellas Pharma US IncMyrbetriq$28$34,61355 claims
AstraZenecaFarxiga, Nexium$50$19,69232 claims
Sumitomo Pharma America, Inc.Gemtesa$20$12,70817 claims
AbbVieSynthroid$484$6,82494 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 570 internal medicine providers in Nebraska.

Other internal medicine in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →